盐酸氟桂利嗪原料及其胶囊有关物质检查方法研究

目的：建立高效液相色谱方法对盐酸氟桂利嗪原料及其胶囊中的杂质进行有效分离，并对已知杂质A、B、C、D，未知杂质及杂质总量进行定量分析。方法：使用迪马Platisil ODS（4.6 mm×250 mm，5 μm）色谱柱，以0.04 mol·L^-1四丁基硫酸氢铵（用三乙胺调节pH至3.3）为流动相A，乙腈为流动相B，梯度洗脱，流速1.5 mL·min^-1，检测波长230 nm，柱温30℃，进样量10 μL；采用线性斜率法计算杂质校正因子。结果：在拟定的色谱条件下，盐酸氟桂利嗪主成分色谱峰与相关的杂质完全分离，制剂中的辅料对主成分及有关物质测定无干扰；已知杂质A、C的相对校正因子分别为1.27、1.06；1家企业2批原料的单杂小于0.16%，杂质总量约为0.26%，5家企业5批制剂的单杂小于0.17%，杂质总量为0.20%~0.74%。结论：该方法专属性强，重复性好，可用于盐酸氟桂利嗪原料及其胶囊有关物质的检查。  

Objective:To establish an HPLC method for the effective separation of flunarizine hydrochloride and its impurities in raw material and capsules,and to carry out the quantitative analysis for analyzing known impurities A,B,C,D,unknown impurities as well as total impurity. Methods:Platisil ODS(4.6 mm×250 mm,5 μm) was adopted as chromatographic column,and using 0.04 mol·L^-1 tetrabutyl ammonium hydrogen sulfate(adjust pH 3.3 by triethylamine) as mobile phase A,acetonitrile as mobile phase B,with a gradient elution. The flow rate was 1.5 mL·min^-1,the detection wavelength was 230 nm,the column temperature was 30℃ and the injection volume was 10 μL. Results:Under the proposed chromatographic conditions,the principal component chromatographic peak of flunarizine hydrochloride and the related substances were separated completely,and the auxiliary material in the capsules did not interfere in the determination of principal component and raw material. The relative correction factors of specified impurities A and C were measured by standard curve method as 1.27 and 1.06 respectively. The individual impurity of two batches of API from one pharmaceutical company was less than 0.16%,and the total amount of impurity was about 0.26%. The individual impurity of five batches of API from five pharmacetical companies was less than 0.17% and the total amount of impurity ranged from 0.20% to 0.74%. Conclusion:This method has strong specificity and good reproducibility,and it can be applied in the examination of the related substances of flunarizine hydrochloride and its capsules. 

[1] CIVELEK E,SOLMAZ I,ONAL MB,et al.Comparison of intrathecal flunarizine and nimodipine treatments in cerebral vasospasm after experimental subarachnoid hemorrhage in rabbits[J].Acta Neurochir Suppl(Wien),2011,110(Pt 2):69
[2] 李桂英.盐酸氟桂利嗪治疗脑动脉硬化症的疗效和安全性分析[J].中国临床新医学,2015,8(9):839 LI GY.Analysis of the efficacy and safety of flunarizine hydrochloride in the treatment of cerebral arteriosclerosis[J].Chin J New Clin Med,2015,8(9):839
[3] 蒋贽.复方丹参滴丸联合盐酸氟桂利嗪治疗慢性脑供血不足临床观察[J].中医药临床杂志,2016,28(1):41 JIANG Y.To observe the clinical curative effect of compound Danshen dropping pills combined flunarizine hydrochloride capsules in the treatment of chronic cerebral circulatory insufficiency[J].Clin J Tradit Chin Med,2016,28(1):41
[4] 王泽民.当代结构药物全集[M].北京:科学技术出版社,1991:4520 WANG ZM.Complete Works of Structural Drugs[M].Beijing:Scientific and Technological Publishers,1991:4520
[5] ORRENIUS S,McCABE JrMJ,NICOTERA P.Ca²⁺-dependent mechanisms of cytotoxicity and programmed cell death[J].Toxicol Lett,1992,64-65:357
[6] ORRENIUS S,NICOTERA P.The calcium ion and cell death[J].J Neural Transm,1994,43:1
[7] KASS GE,ORRENIUS S.Calcium signaling and cytotoxicity[J].Environ Health Persp,1999,107(Suppl 1):25
[8] 敖艳霞.西比灵的药理作用及临床应用[J].中国保健营养,2013,3(下):1427 AO YX.The pharmacological function and clinical application of flunarizine[J].China Health Nutr,2013,3(2nd Vol):1427
[9] 卢文琴,尹航.盐酸氟桂利嗪胶囊的临床研究与药理作用[J].中国现代药物应用,2012,6(19):130 LU WQ,YIN H.Clinical study and pharmacological action of flunarizine hydrochloride capsules[J].Chin J Mod Drug Appl,2012,6(19):130
[10] 张卫军.眩晕宁薄膜衣片与盐酸氟桂利嗦胶囊治疗系统性眩晕的临床对照[J].中国医院药学杂志,2011,31(13):1110 ZHANG WJ.A clinical study of the effect of Xuanyunning filmlok and sebilium capsule on systemic dizziness disease[J].Chin Hosp Pharm,2011,31(13):1110
[11] 中华人民共和国药典2015年版.二部[S].2015:1038 ChP 2015.Vol Ⅱ[S].2015:1038
[12] EP 9.0[S].2017:2494
[13] BP 2017[S].2017:Ⅰ-1010